E
ACAD icon

Ergoteles’s Acadia Pharmaceuticals ACAD Stock Holding History

Ergoteles’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-52,188
Closed -$1.25M – 30
2023
Q2 		$1.25M Buy
52,188
+16,062
+44% +$357K 0.06% 396
2023
Q1 		$680K Sell
36,126
-101,429
-74% -$1.93M 0.03% 634
2022
Q4 		$2.19M Sell
137,555
-120,742
-47% -$1.89M 0.08% 253
2022
Q3 		$4.23M Buy
258,297
+240,741
+1,371% +$3.9M 0.15% 147
2022
Q2 		$247K Buy
+17,556
New +$328K 0.01% 1210
2022
Q1 		– Sell
-26,637
Closed -$622K – 1167
2021
Q4 		$622K Buy
26,637
+4,211
+19% +$84.7K 0.02% 565
2021
Q3 		$372K Buy
+22,426
New +$432K 0.01% 709
2021
Q2 		– Sell
-161,892
Closed -$4.18M – 1458
2021
Q1 		$4.18M Buy
161,892
+97,758
+152% +$4.3M 0.13% 186
2020
Q4 		$3.43M Buy
+64,134
New +$3.18M 0.11% 186

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Ergoteles's ACAD Position: Q3 2023 in Review

Ergoteles sold out of Acadia Pharmaceuticals (ACAD) in Q3 2023, closing a stake of 52,188 shares — an estimated $1.25M sold.

Ergoteles first reported a position in ACAD in Q4 2020 and held it in 9 quarters. The position peaked at $4.23M in Q3 2022. 247 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

  • Ergoteles reported no remaining Acadia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 52,188 Acadia Pharmaceuticals shares in Q3 2023, an estimated $1.25M.
  • Ergoteles first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • Ergoteles's Acadia Pharmaceuticals position peaked at $4.23M in Q3 2022.
  • 247 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.